{
    "name": "lamivudine/raltegravir",
    "comment": "Rx",
    "other_names": [
        "Dutrebis"
    ],
    "classes": [
        "HIV",
        "ART Combos"
    ],
    "source": "https://reference.medscape.com/drug/dutrebis-lamivudine-raltegravir-1000015",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Breastfeeding is not recommended while taking lamivudine/raltegravir; additionally it is recommended that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Breastfeeding is not recommended while taking lamivudine/raltegravir; additionally it is recommended that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of NRTIs alone or in combination, including lamivudine and other antiretrovirals",
                "Post-treatment exacerbations of hepatitis in patients with HIV-1 and hepatitis B virus coinfection reported",
                "Pancreatitis reported; use with caution in pediatric patients with a history or prior antiretroviral nucleoside exposure, a history of pancreatitis, or other risk factors for pancreatitis; discontinue immediately if signs or symptoms of pancreatitis occur",
                "Hepatic decompensation reported with used with interferon- or ribavirin-based regimens; ribavirin can reduce the phosphorylation of pyrimidine NRTIs such as lamivudine",
                "Severe, potentially life-threatening, and fatal skin reactions reported with raltegravir, including Stevens-Johnson syndrome and toxic epidermal necrolysis; hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure; discontinue if signs or symptoms occur",
                "Immune reconstitution syndrome reported with combination antiretroviral therapy and may include an inflammatory response to indolent or residual opportunistic infections or emergence of autoimmune disorders (eg, Grave disease, polymyositis, Guillain-Barré syndrome)",
                "Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” reported with ARTs",
                "Not recommended in combination with products containing the individual components (ie, lamivudine and raltegravir) or emtricitabine"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide decreases levels of raltegravir by cation binding in GI tract. Contraindicated. Not  recommended with or without dose separation."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aluminum hydroxide/magnesium carbonate",
            "description": {
                "common": "aluminum hydroxide/magnesium carbonate will decrease the level or effect of raltegravir by  enhancing GI absorption. Applies only to oral form of both agents. Contraindicated. Not recommended with or without dose separation"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aluminum hydroxide/magnesium trisilicate",
            "description": {
                "common": "aluminum hydroxide/magnesium trisilicate will decrease the level or effect of raltegravir by  enhancing GI absorption. Applies only to oral form of both agents. Contraindicated. Not recommended with or without dose separation"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "lamivudine, elvitegravir/cobicistat/emtricitabine/tenofovir DF. Other (see comment). Contraindicated. \nComment: Elvitegravir/cobicistat/emtricitabine/tenofovir is a complete regimen for HIV and should not be administered with other antiretrovirals."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "emtricitabine and lamivudine both increase  risk of immune reconstitution syndrome. Contraindicated. Coadministration of emtricitabine containing products and lamivudine containing products should be avoided. Combination will result in therapeutic duplication."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "magnesium supplement",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of raltegravir by  Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "raltegravir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabotegravir",
            "description": {
                "common": "raltegravir, cabotegravir. Other (see comment). Avoid or Use Alternate Drug. \nComment: Cabotegravir plus rilpivirine is a complete regimen. Coadministration with other antiretroviral medications for treating HIV-1 infection is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, raltegravir.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Patients should not take antiretroviral medications for at least 1 month before initiating medications for stem cell mobilization, for the duration of the medications? elimination, and until all cycles of apheresis are completed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "magnesium hydroxide will decrease the level or effect of raltegravir by  cation binding in GI tract. Avoid or Use Alternate Drug. Magnesium containing antacids reduce raltegravir plasma levels when taken within 6 hr of raltegravir dose"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sorbitol",
            "description": {
                "common": "sorbitol will decrease the level or effect of lamivudine by  Other (see comment). Avoid or Use Alternate Drug. Sorbitol-containing solution decreased systemic exposure of lamivudine oral solution in a pediatric study (ARROW trial). Results showed lower rates of virologic suppression, lower plasma lamivudine exposure, and development of viral resistance more frequently than children receiving lamivudine tablets."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride decreases levels of raltegravir by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate decreases levels of raltegravir by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tafenoquine",
            "description": {
                "common": "tafenoquine will increase the level or effect of lamivudine by  Other (see comment). Avoid or Use Alternate Drug. Tafenoquine inhibits organic cation transporter-2 (OCT2) and multidrug and toxin extrusion (MATE) transporters in vitro. Avoid coadministration with OCT2 or MATE substrates. If coadministration cannot be avoided, monitor for substrate-related toxicities and consider dosage reduction if needed based on product labeling of the coadministered drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abacavir",
            "description": {
                "common": "abacavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of raltegravir by  increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and may decrease systemic exposure of drugs that are UGT substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "lamivudine will increase the level or effect of cabozantinib by  Other (see comment). Use Caution/Monitor. MRP2 inhibitors increase cabozantinib toxicity"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enfuvirtide",
            "description": {
                "common": "enfuvirtide and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "lamivudine increases levels of erdafitinib by decreasing renal clearance. Modify Therapy/Monitor Closely. Consider alternatives that are not OCT2 substrates or consider reducing the dose of OCT2 substrates based on tolerability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will decrease the level or effect of raltegravir by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "ganciclovir, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Increased risk of hematologic toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "nirmatrelvir will decrease the level or effect of raltegravir by  Other (see comment). Use Caution/Monitor. Raltegravir is an UGT1A1 substrate. Ritonavir induces UGT 1A1."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "interferon alfa 2b",
            "description": {
                "common": "interferon alfa 2b, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of liver decompensation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "lamivudine and nevirapine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will decrease the level or effect of raltegravir by  Other (see comment). Use Caution/Monitor. Raltegravir is an UGT1A1 substrate. Ritonavir induces UGT 1A1."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat will decrease the level or effect of raltegravir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "peginterferon alfa 2a, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of liver decompensation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of raltegravir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Rifabutin induces UGT1A1 "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2b",
            "description": {
                "common": "peginterferon alfa 2b, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of liver decompensation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribavirin",
            "description": {
                "common": "ribavirin increases toxicity of lamivudine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Use alternatives if available. Increased risk of lactic acidosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin decreases levels of raltegravir by increasing hepatic clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selenium",
            "description": {
                "common": "selenium will decrease the level or effect of raltegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer raltegravir at least 2 h before or 6 h after polyvalent cations. Note: Dose separation may not adequately avoid this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium zirconium cyclosilicate",
            "description": {
                "common": "sodium zirconium cyclosilicate will increase the level or effect of raltegravir by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Check specific recommendations for drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy. In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stavudine",
            "description": {
                "common": "lamivudine and stavudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "lamivudine and tenofovir DF both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "trimethoprim increases effects of lamivudine by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. Potential for increased toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of raltegravir by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valganciclovir",
            "description": {
                "common": "valganciclovir, lamivudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Use alternatives if available.  Increased risk of hematologic toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zinc",
            "description": {
                "common": "zinc will decrease the level or effect of raltegravir by  cation binding in GI tract. Modify Therapy/Monitor Closely. Administer raltegravir 2 hr before or 6 hr after administration of polyvalent cation containing products."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "isavuconazonium sulfate will increase the level or effect of lamivudine by  Other (see comment). Minor/Significance Unknown. Isavuconazonium sulfate, an OCT2 inhibitor, may increase the effects or levels of OCT2 substrates."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole increases levels of lamivudine by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zidovudine",
            "description": {
                "common": "lamivudine increases effects of zidovudine by pharmacodynamic synergism. Minor/Significance Unknown. Beneficial synergism."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cough",
            "percent": "16"
        },
        {
            "name": "Diarrhea",
            "percent": "9"
        },
        {
            "name": "Fatigue and malaise",
            "percent": "9"
        },
        {
            "name": "Fever",
            "percent": "9"
        },
        {
            "name": "pediatric",
            "percent": "8"
        },
        {
            "name": "Headache",
            "percent": "6"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "5"
        },
        {
            "name": "Nausea",
            "percent": "5"
        },
        {
            "name": "Nervous system neuropathy",
            "percent": "5"
        },
        {
            "name": "Pancreatitis",
            "percent": "4"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "4"
        },
        {
            "name": "Nasal S",
            "percent": "4"
        },
        {
            "name": "S",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "Total cholesterol increased",
            "percent": "3"
        },
        {
            "name": "Abdominal cramps",
            "percent": null
        },
        {
            "name": "abdominal pain",
            "percent": null
        },
        {
            "name": "Anorexia and",
            "percent": null
        },
        {
            "name": "or decreased appetite",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Creatine phosphokinase increased",
            "percent": null
        },
        {
            "name": "AST increased",
            "percent": null
        },
        {
            "name": "Glucose increased",
            "percent": null
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Nasopharyngitis",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Extremity pain",
            "percent": null
        },
        {
            "name": "Influenza",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Asthenia GI disorders",
            "percent": null
        },
        {
            "name": "Lipodystrophy",
            "percent": null
        },
        {
            "name": "Skin disorders",
            "percent": null
        },
        {
            "name": "Drug related hypersensitivity",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Suicidal ideation",
            "percent": null
        },
        {
            "name": "Body fat redistribution",
            "percent": null
        },
        {
            "name": "Elevated amylase",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Hepatitis B exacerbation",
            "percent": null
        },
        {
            "name": "Cerebellar ataxia",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Hepatic failure",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "particularly in patients with a pre",
            "percent": null
        },
        {
            "name": "existing history of psychiatric illness",
            "percent": null
        },
        {
            "name": "including suicidal ideation and behaviors",
            "percent": null
        },
        {
            "name": "paranoia",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "Steven",
            "percent": null
        },
        {
            "name": "s",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        }
    ]
}